Literature DB >> 21585246

High blood hemoglobin concentration as risk factor of major atherosclerotic cardiovascular events in 114,159 healthy men and women in the apolipoprotein mortality risk study (AMORIS).

Ingar Holme1, Are H Aastveit, Niklas Hammar, Ingmar Jungner, Göran Walldius.   

Abstract

BACKGROUND: Few studies have tested differences in relationships between hemoglobin (Hb) and long-term risk of major cardiovascular diseases according to age and gender in healthy subjects as opposed to anemia. AIMS: Such relationships were examined and risk-tested in relation to Hb values in the Apolipoprotein MOrtality RISk (AMORIS) Study.
METHODS: Using data from AMORIS and the Swedish hospital discharge and mortality registers, a prospective cohort study of 114,159 subjects with mean follow-up of 11.8 years, the association between Hb and risk of acute myocardial infarction (AMI), ischemic stroke (IS), and congestive heart failure (CHF) by Cox regression analysis according to age and gender was studied.
RESULTS: Elevated Hb levels were associated to acute myocardial infarction (AMI) (HR 1.10 (1.06-1.13) per SD change), mostly confined to men and younger subjects but with greater sex similarity trends for CHF. Slightly increased risks were seen for the lowest Hb levels in the elderly and in females. IS risk was positively and more linearly associated to Hb.
INTERPRETATION: In AMORIS the highest AMI and CHF risks were found in the upper region of the distribution, but different shapes of relationships according to age and gender were found. IS associated positively with Hb. Key words:

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21585246     DOI: 10.3109/07853890.2011.573804

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  7 in total

1.  NFAT regulates the expression of AIF-1 and IRT-1: yin and yang splice variants of neointima formation and atherosclerosis.

Authors:  Lisa M Berglund; Olga Kotova; Peter Osmark; Helena Grufman; Chen Xing; Marie-Louise Lydrup; Isabel Goncalves; Michael V Autieri; Maria F Gomez
Journal:  Cardiovasc Res       Date:  2011-11-23       Impact factor: 10.787

2.  Model comparisons of competing risk and recurrent events for graft failure in renal transplant recipients.

Authors:  Ingar Holme; Bengt C Fellström; Alan G Jardine; Anders Hartmann; Hallvard Holdaas
Journal:  Clin J Am Soc Nephrol       Date:  2012-11-15       Impact factor: 8.237

3.  High haemoglobin levels and mortality in males with intracerebral haemorrhage: a retrospective cohort study.

Authors:  Shuting Zhang; Yang Shu; Wenjing Li; Chenchen Wei; Aiping Deng; Yajun Cheng; Peng Lei; Ming Liu
Journal:  BMJ Open       Date:  2022-01-04       Impact factor: 2.692

4.  Hemoglobin concentration and risk of cardiovascular disease in Korean men and women - the Korean heart study.

Authors:  Moo-Young Kim; Sun Ha Jee; Ji Eun Yun; Soo Jin Baek; Duk-Chul Lee
Journal:  J Korean Med Sci       Date:  2013-08-28       Impact factor: 2.153

5.  Association of Alk1 and Endoglin Polymorphisms with Cardiovascular Damage.

Authors:  Mercedes Garzon-Martinez; Nuria Perretta-Tejedor; Luis Garcia-Ortiz; Manuel A Gomez-Marcos; Rogelio Gonzalez-Sarmiento; Francisco J Lopez-Hernandez; Carlos Martinez-Salgado
Journal:  Sci Rep       Date:  2020-06-10       Impact factor: 4.379

6.  Association of serum hemoglobin level with the risk of carotid plaque beyond metabolic abnormalities among asymptomatic adults without major adverse clinical events: a cross-sectional cohort study.

Authors:  Yunsuk Choi; Ki-Bum Won; Hyeon Hui Kang; Hyuk-Jae Change
Journal:  BMC Cardiovasc Disord       Date:  2021-03-02       Impact factor: 2.298

7.  Association Between Changes in Hemoglobin Concentration and Cardiovascular Risks and All-Cause Mortality Among Young Women.

Authors:  Gyeongsil Lee; Seulggie Choi; Kyuwoong Kim; Jae-Moon Yun; Joung Sik Son; Su-Min Jeong; Sung Min Kim; Yeon-Yong Kim; Seong Yong Park; Youngil Koh; Seung-Sik Hwang; Sang Min Park
Journal:  J Am Heart Assoc       Date:  2018-08-21       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.